Fox Chase Cancer Center | Strategic Alliance Partners

May 31, 2023

Fox Chase Cancer Center’s Mary Daly, MD, PhD, FACP was recently recognized as the first recipient of the BRCA Impact Award from Penn Medicine’s Basser Center for BRCA.

May 30, 2023

STAT2 expression in patients with hepatocellular carcinoma increases with tumor grade and cancer stage, with increases occurring at greater rates among Asian and African American patients.

May 29, 2023

Latinx patients with cancer had a low rate of tumor genomic profiling, partially due to structural and cultural barriers, according to findings from a qualitative study presented during the 5th Annual Regional SPEECH Conference and Retreat.

May 26, 2023

Individuals in Philadelphia and New York City who were screened for the common liver cancer risk factors hepatitis B virus or hepatitis C virus displayed a higher level of knowledge of liver cancer.

May 26, 2023

Austin D. Williams, MD, MSEd, of Fox Chase Cancer Center, received the Best Poster Award at the recent 24th Annual Meeting of the American Society of Breast Surgeons.

May 23, 2023

Young investigators, fellows, and medical students recently gathered at the Temple University Lewis Katz School of Medicine in Philadelphia, Pennsylvania, to network and share exciting research aimed at addressing disparities in the dissemination of cancer care at the 5th Annual Regional Synergistic Partnership for Enhancing Equity in Cancer Health Conference and Retreat.

May 22, 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

May 12, 2023

Matthew Lee, MD, MBA, discusses his use of a new robotic laparoscopic procedure to treat a complication caused by cancer radiation therapy at the 2023 American Urological Association Annual Meeting.

May 10, 2023

Fox Chase Cancer Center is pleased to announce the hiring of Abigail T. Berman, MD, MSCE, as an assistant professor in the Department of Radiation Oncology.

May 04, 2023

Fox Chase Cancer Center and Temple Health are pleased to announce the new Fox Chase-Temple Urologic Institute, a groundbreaking initiative that will concentrate on both benign and oncologic urology.

May 01, 2023

Faculty across 4 institutions discuss their participation in a 4-team initiative launched by Stand Up To Cancer® that focuses on expanding access to cancer care and research.

May 01, 2023

Christian Hurtz, PhD, an assistant professor at the Fels Cancer Institute for Personalized Medicine at the Lewis Katz School of Medicine at Temple University, has been awarded a four-year $800,000 A-Award by Alex’s Lemonade Stand Foundation for Childhood Cancer.

April 27, 2023

Fox Chase Cancer Center is pleased to announce the hiring of Maryam Ijaz Khan, MD, as an associate professor in the Division of Endocrinology.

April 25, 2023

Edna “Eti” Cukierman, PhD, was been appointed chair-elect of the AACR Tumor Microenvironment Working Group at the AACR Annual Meeting 2023.

April 21, 2023

Erin Longstreth-Papsun, RN, MSN, OCN, NEA-BC, clinical director of Ambulatory Satellite Clinics and Radiation Oncology Nursing at Fox Chase Cancer Center, was recently awarded the Excellence in Cancer Nursing Management Award by the Oncology Nursing Society (ONS).

April 12, 2023

Fox Chase Cancer Center and Temple Health are kicking off National Donate Life Month with a Be The Match virtual event.

March 30, 2023

Fox Chase Cancer Center and Temple Health are pleased to announce the hiring of Claire L. Streibert, MD, as site chief of breast imaging.

March 17, 2023

Martin Edelman, MD, and Linda Fleisher, PhD, MPH, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

March 17, 2023

A new study by Fox Chase Cancer Center scientists shows how DNA methylation can regulate the immune response in colorectal cancer, laying the groundwork for potential new treatments. .

March 15, 2023

Researchers at Fox Chase Cancer Center have begun recruiting for a clinical trial called PRESERVE that will evaluate the safety and efficacy of the NanoKnife System to treat patients with intermediate-risk prostate cancer.